{
    "clinical_study": {
        "@rank": "99006", 
        "acronym": "TRYHARD", 
        "arm_group": [
            {
                "arm_group_label": "Radiation therapy + cisplatin + placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Radiation therapy + cisplatin + lapatinib", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of\n      radiation therapy plus cisplatin in patients who have head and neck cancer that is not\n      related to the HPV virus."
        }, 
        "brief_title": "TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.", 
        "completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-HPV Locally Advanced Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": "Head and Neck Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients must have histologically or cytologically confirmed Squamous Cell  Cancer of\n             the oropharynx, hypopharynx or larynx (For patients with oropharynx primary, the\n             tumor must be negative for p16 by immunohistochemistry).\n\n          -  Patients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b,\n             N2c or N3p16 negative oropharynx cancer or T1-2 any N hypopharynx cancer) including\n             no distant metastases.\n\n          -  History/Physical examination by a Radiation Oncologist and Medical oncologist prior\n             to entering the study.\n\n          -  Examination by an ENT or Head & Neck Surgeon including laryngopharyngoscopy prior to\n             entering the study.\n\n          -  Patients must have a chest CT scan, or PET/CT scan to rule out metastatic disease\n\n          -  Patients must have a CT scan, MRI, or PET/CT scan of the tumor site and neck nodes\n             prior to entering the study.\n\n          -  Patients must have an EKG and ECHO or MUGA scan prior to entering the study.\n\n          -  Patients must have Zubrod Performance Status of 0-1.\n\n          -  Patients must be \u2265 18 years of age.\n\n          -  Patients must have normal organ and marrow function as defined below:\n\n               -  Absolute neutrophil count (ANC) \u2265 1,500 cells/mm3\n\n               -  Platelets \u2265 100,000 cells/mm3\n\n               -  Hemoglobin \u2265 8.0 g/dl\n\n               -  Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) \u2265 50 ml/min\n\n               -  Total bilirubin < 2 x the institutional upper limit of normal\n\n               -  AST or ALT \u2264  3 x the institutional upper limit of normal\n\n          -  Patient must have magnesium, calcium, glucose, potassium and sodium levels within\n             normal limits\n\n          -  Women of childbearing potential must have a negative pregnancy test prior to\n             registration.\n\n          -  Patients of reproductive potential must practice effective contraception while on\n             study and for at least 60 calendar days following treatment.\n\n          -  All patients must sign an informed consent prior to enrollment.\n\n          -  Patients must comply with the treatment plan and follow-up schedule.\n\n        Exclusion criteria:\n\n          -  Patients with simultaneous primaries or bilateral tumors.\n\n          -  Patients who have had gross total excision of the primary tumor.\n\n          -  Patients with initial surgical treatment, radical or modified neck dissection.\n\n          -  Patients who received prior systemic chemotherapy for the study cancer.\n\n          -  Patients who received prior radiotherapy to the region of the study cancer that would\n             result in overlap of radiation therapy fields.\n\n          -  Patients with primary tumor of oral cavity, nasopharynx, sinuses or salivary glands.\n\n          -  Prior allergic reaction to the study drugs.\n\n          -  Patients who have had prior therapy that specifically and directly targets the\n             EGFR/HER2 pathway.\n\n          -  Patients who have current active hepatic or biliary disease (with exception of\n             patients with Gilbert's syndrome, asymptomatic gallstones, or stable chronic liver\n             disease per investigator assessment);\n\n          -  Pregnant women or sexually active patients not willing or able to use medically\n             acceptable forms of contraceptive method while on treatment.\n\n          -  Patients with severe, active co-morbidity, defined as follows:\n\n               -  Uncontrolled cardiac disease, such as uncontrolled hypertension, unstable\n                  angina, and/or congestive heart failure requiring hospitalization within the\n                  last 6 months\n\n               -  Transmural myocardial infarction within the last 6 months\n\n               -  Left ventricular ejection fraction < 45%\n\n               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the\n                  time of registration\n\n               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness\n                  requiring hospitalization or precluding study therapy within 30 calendar days\n                  prior to registration\n\n               -  Hepatic insufficiency resulting in clinical jaundice and/or Coagulation defects\n\n               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "176", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711658", 
            "org_study_id": "RF-3501", 
            "secondary_id": "LAP116153"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Radiation therapy + cisplatin + placebo", 
                    "Radiation therapy + cisplatin + lapatinib"
                ], 
                "description": "70 Gy in 2 Gy fractions", 
                "intervention_name": "intensity modulated radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Radiation therapy + cisplatin + placebo", 
                    "Radiation therapy + cisplatin + lapatinib"
                ], 
                "description": "100 mg/m2 on days 8 and 29", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Radiation therapy + cisplatin + placebo", 
                "description": "1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 12 months", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Radiation therapy + cisplatin + lapatinib", 
                "description": "1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 12 months", 
                "intervention_name": "Lapatinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lapatinib", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Clinical Trials Office - University of Alabama at Birmingham C", 
                    "phone": "205-934-0309"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama at Birmingham Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nayana L. Vora, MB, BS", 
                    "phone": "626-359-8111"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010-3000"
                    }, 
                    "name": "City of Hope Comprehensive Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lmell@ucsd.edu", 
                    "last_name": "Loren Mell, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093"
                    }, 
                    "name": "University of California, San Diego"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jonesc@radiological.com", 
                    "last_name": "Christopher Jones"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95816"
                    }, 
                    "name": "Radiological Associates - Sacramento"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yoms@radonc.ucsf.edu", 
                    "last_name": "Sue S Yom, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California San Francisco"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cctoffice@stanford.edu", 
                    "last_name": "Clinical Trials Office - Stanford Cancer Center", 
                    "phone": "650-498-7061"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5824"
                    }, 
                    "name": "Stanford Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jonathan J. Beitler", 
                    "phone": "404-686-4411"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shiao Y. Woo", 
                    "phone": "502-562-4158"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "James Graham Brown Cancer Center at University of Louisville"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "yuhchyau_chen@urmc.rochester.edu", 
                    "last_name": "Yuhchyau Chen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "min.yao@uhhospitals.org", 
                    "last_name": "Min Yao"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "University Hospitals of Cleveland"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "maura.gillison@osumc.edu", 
                    "last_name": "Maura L Gillison, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "terence-herman@ouhsc.edu", 
                    "last_name": "Terrance Herman, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73190"
                    }, 
                    "name": "University of Oklahoma Health Sciences Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.galloway@fccc.edu", 
                    "last_name": "Thomas Galloway, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Furlong", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18925"
                    }, 
                    "name": "Fox Chase Cancer Center Buckingham"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "john.yordy@utsouthwestern.edu", 
                    "last_name": "John Yordy, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "University of Texas Southwestern Medical School"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gbgunn@mdanderson.org", 
                    "last_name": "Brandon Gunn, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas - MD Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul M. Harari", 
                    "phone": "608-263-8500"
                }, 
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "swong@mcw.edu", 
                    "last_name": "Stuart Wong, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Medical College of Wisconsin"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "George Shenouda", 
                    "phone": "514-398-1444"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2W 1S6"
                    }, 
                    "name": "McGill Cancer Centre at McGill University"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb\u00ae) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation", 
        "overall_contact": {
            "email": "swong@mcw.edu", 
            "last_name": "Stuart Wong, MD"
        }, 
        "overall_official": {
            "affiliation": "Medical College of Wisconsin", 
            "last_name": "Stuart Wong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The time from randomization until local, regional, or distant disease progression, or death.", 
            "measure": "Progression-Free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "reference": {
            "citation": "Harrington K. et al. Phase II study of oral Lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 28:15s, 2010 suppl. Abstract 5505. GSK study 884"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711658"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The time from randomization until development of distant metastasis.", 
                "measure": "Distant metastasis", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Data is collected during protocol treatment and 30 days after whether or not related to the study drug.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Participants are followed for up to 17 months from the start of treatment"
            }, 
            {
                "measure": "Compliance with planned treatment", 
                "safety_issue": "Yes", 
                "time_frame": "maintenance therapy is 12 months and could be different for each patient."
            }, 
            {
                "description": "The time from randomization until local-regional recurrence or progression.", 
                "measure": "Local-regional failure", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Performance Status Scale for Head & Neck Cancer.", 
                "safety_issue": "No", 
                "time_frame": "3 months, 1 year, and 2 years"
            }, 
            {
                "measure": "Functional Assessment of Cancer Therapy - Head & Neck.", 
                "safety_issue": "No", 
                "time_frame": "3 months, 1 year, and 2 years."
            }, 
            {
                "measure": "University of Michigan Xerostomia-Related Quality of Life Scale.", 
                "safety_issue": "No", 
                "time_frame": "3 months, 1 year, and 2 years."
            }, 
            {
                "measure": "HER2, EGFR, EMT as biomarkers of response.", 
                "safety_issue": "No", 
                "time_frame": "End of Study"
            }, 
            {
                "description": "The time from randomization until death", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Radiation Therapy Oncology Group", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Radiation Therapy Oncology Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}